BCPP

Blackpoint Cyber Introduces Community Protection Program

Retrieved on: 
Wednesday, March 6, 2024

ELLICOTT CITY, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Blackpoint Cyber (Blackpoint), the leading provider of world-class cybersecurity solutions, today announced the new Blackpoint Community Protection Program (BCPP).

Key Points: 
  • ELLICOTT CITY, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Blackpoint Cyber (Blackpoint), the leading provider of world-class cybersecurity solutions, today announced the new Blackpoint Community Protection Program (BCPP).
  • Blackpoint was the first cybersecurity company to discover and validate this issue, quickly recommending that customers patch and upgrade to the new version.
  • Threat Assessment Summary – monthly, comprehensive reports showing exposures across the attack surface so MSPs can provide proactive protection to their clients.
  • Blackpoint University – The only ‘MBA for MSPs’ program, launched new courses that deliver practical advice from industry and domain experts on how to sell, promote, and scale a business effectively.

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Retrieved on: 
Tuesday, February 6, 2024

CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.

Key Points: 
  • CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.
  • To register, click here .
  • The event will focus on reviewing Reviva's positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the Company's ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
  • A live question and answer session will follow the formal presentations.

Balega Debuts Tenth Annual Limited-Edition Grit and Grace Sock Collection

Retrieved on: 
Friday, October 6, 2023

DURHAM, N.C., Oct. 6, 2023 /PRNewswire/ -- Balega, a leading performance running sock brand, proudly announces its release of their tenth annual, limited-edition Grit and Grace collection.

Key Points: 
  • DURHAM, N.C., Oct. 6, 2023 /PRNewswire/ -- Balega, a leading performance running sock brand, proudly announces its release of their tenth annual, limited-edition Grit and Grace collection.
  • The socks in this collection feature Balega's world-class quality of exceptional comfort, fit and durability.
  • "We are proud to reach this ten-year milestone for our Grit and Grace collection," said Michael Polk, Chief Executive Officer of Implus.
  • Grit and Grace socks will retail for $17 per pair and can be purchased at specialty run stores and online at www.balega.com .

Sage Growth Partners Releases New Patient Safety Report Providing Cross-Sector Insights from Hospitals, Health Systems, Non-Profit Organizations and Technology Companies

Retrieved on: 
Tuesday, October 3, 2023

BALTIMORE, October 3, 2023 /PRNewswire/ -- Sage Growth Partners (SGP), a nationally recognized healthcare research, strategy, and marketing firm, has released a new cross-sector safety report that provides perspectives on hospital patient safety challenges, improvement opportunities and how healthcare organizations can best advance positive changes.

Key Points: 
  • BALTIMORE, October 3, 2023 /PRNewswire/ -- Sage Growth Partners (SGP), a nationally recognized healthcare research, strategy, and marketing firm, has released a new cross-sector safety report that provides perspectives on hospital patient safety challenges, improvement opportunities and how healthcare organizations can best advance positive changes.
  • The new report, Leading Through Change: Because Patients Deserve More , offers insights from industry leaders within hospitals, health systems, non-profit organizations, and technology companies.
  • Key insights and dialogue points of the report, include:
    What is the biggest patient safety gain that has occurred in the past decade?
  • While these conversations have revealed that most hospitals are prioritizing patient safety improvements, safety errors and adverse events continue to plague even the best organizations.

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Retrieved on: 
Tuesday, April 25, 2023

He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.

Key Points: 
  • He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.
  • The Reviva leadership team will provide an overview of the efficacy and safety data generated in the clinical trials completed to date and an update on ongoing RECOVER Phase 3 trial evaluating brilaroxazine in patients with acute schizophrenia.
  • Brilaroxazine is a new chemical entity with broad therapeutic potential in neuropsychiatric and inflammatory conditions arising from underlying dysfunction in serotonin and dopamine signaling.
  • Dr. Ereshefsky’s unique perspective as a clinical scientist (clinical psychiatric pharmacist and psychopharmacologist) helps to guide drug development from preclinical to late Phase.

Research by Husson Pharmacy Faculty and PCHC Colleague Describes Second-Year Pharmacy Residency Growth

Retrieved on: 
Thursday, March 9, 2023

The research was completed by two faculty members from the Husson University School of Pharmacy.

Key Points: 
  • The research was completed by two faculty members from the Husson University School of Pharmacy.
  • They are Dr. Drew Lambert, BCPS, an associate professor of pharmacy practice and Dr. Shannon M. James, BCPP, an assistant professor of pharmacy practice.
  • Prior to joining PCHC , Welch was an assistant professor of pharmacy practice at Husson’s School of Pharmacy from August 2019 - August 2021.
  • The School of Pharmacy is just one of several schools that are a part of Husson University’s College of Health and Pharmacy.

Innersense Organic Beauty Advocates for Safe Ingredients to Reduce Breast Cancer

Retrieved on: 
Wednesday, December 28, 2022

CONCORD, Calif., Dec. 28, 2022 /PRNewswire-PRWeb/ -- Innersense Organic Beauty has donated over $90,000 to nonprofit Breast Cancer Prevention Partners (BCPP) so far in 2022, with continued contributions for its annual Season of Giving campaign, which spans five weeks each year. The brand chose BCPP as its designated cause partner for week two, November 28 to December 4, which included Giving Tuesday.

Key Points: 
  • "Giving back to purposeful organizations was part of our original intentions when launching Innersense Organic Beauty.
  • BCPP shares our mission to remove toxic chemicals from beauty and personal care products," shares Greg Starkman, CEO of Innersense Organic Beauty.
  • Innersense Organic Beauty was born out of a quest for clean, safe ingredients after the Starkmans' daughter was diagnosed with Williams Syndrome at 22 months old.
  • Every formula in the Innersense Organic Beauty line is made with sustainably sourced ingredients and is free of synthetics.

CE Concepts Receives Joint Accreditation with Commendation, the Highest Level of Accreditation for Continuing Medical Education Providers

Retrieved on: 
Wednesday, December 21, 2022

LEXINGTON, Ky., Dec. 21, 2022 /PRNewswire/ -- Creative Educational Concepts, LLC (CEC), an accredited provider of interprofessional continuing medical education (CME) and a division of KnowFully Learning Group, today announced it received Joint Accreditation with Commendation, the highest level of accreditation offered to members of its industry. The designation runs through November 2028, solidifying CEC's standing as a long-term leader in training and education for healthcare providers.

Key Points: 
  • The designation runs through November 2028, solidifying CEC's standing as a long-term leader in training and education for healthcare providers.
  • "Receiving Joint Accreditation with Commendation validates CE Concepts as a premier source of accredited continuing education within the healthcare community," said Joni Fowler, PharmD, BCPP, CEC founder and managing director.
  • "Achieving Joint Accreditation with Commendation is a real achievement in this industry," said Susan Yarbrough, CHCP, senior director, educational excellence, for KnowFully Medical Education.
  • CE Concepts designs, develops and delivers responsive continuing medical education initiatives for physicians, pharmacists, nurses, and related members of the interprofessional healthcare team.

CenExel Creates Clinical Sciences Business Unit

Retrieved on: 
Tuesday, November 15, 2022

Salt Lake City, Utah, Nov. 15, 2022 (GLOBE NEWSWIRE) -- CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus the broader network of CenExel therapeutic experts and key opinion leaders (KOLs), providing support to all the CenExel Centers of Excellence as well as standalone consulting services.

Key Points: 
  • Salt Lake City, Utah, Nov. 15, 2022 (GLOBE NEWSWIRE) -- CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus the broader network of CenExel therapeutic experts and key opinion leaders (KOLs), providing support to all the CenExel Centers of Excellence as well as standalone consulting services.
  • Clinical Sciences by CenExel (Clinical Sciences) offers a unique opportunity for collaboration with pharmaceutical sponsors, CROs, and vendors, to support study development and conduct within the Sponsors clinical development program across the development lifecycle.
  • All told, these elements combine in Clinical Sciences to create a unique, first-of-its-kind, holistic approach in the clinical research industry.
  • Clinical Sciences by CenExel offers unprecedented expertise and experience in study design strategies including complex biomarker studies that can inform key go/no-go decisions.

CEC Oncology to Publish Four Abstracts at the 2022 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022

LEXINGTON, Ky. , May 31, 2022 /PRNewswire/ -- CEC Oncology, the oncology arm of CE Concepts, LLC (CEC) and a subsidiary of KnowFully Learning Group, announces four abstracts accepted for publication in the Professional Development and Education Advances track of the 2022 ASCO Annual Meeting (https://conferences.asco.org/am/attend #ASCO22). ASCO's (American Society of Clinical Oncology) annual meeting is the preeminent oncology meeting in the world, offering premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

Key Points: 
  • LEXINGTON, Ky., May 31, 2022 /PRNewswire/ -- CEC Oncology, the oncology arm of CE Concepts, LLC (CEC) and a subsidiary of KnowFully Learning Group, announces four abstracts accepted for publication in the Professional Development and Education Advances track of the 2022 ASCO Annual Meeting ( https://conferences.asco.org/am/attend #ASCO22).
  • ASCO's (American Society of Clinical Oncology) annual meeting is the preeminent oncology meeting in the world, offering premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.
  • CEC Oncology announces four abstracts accepted for publication at the 2022 ASCO Annual Meeting.
  • CEC Oncology offers accredited education to physicians, pharmacists, nurses, and related members of the healthcare team on topics related to solid tumors and hematologic malignancies.